Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 15/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31396139 | 0.85 | NPY5R (0.48) | NPY5RNOTUM | |
| SCHEMBL17446870 | 0.79 | NOTUM (0.57) | NOTUMPOLBKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL31396031 | 0.77 | NLRP3 (0.61) | NLRP3POLBSMN1; SMN2 | |
| SCHEMBL31330498 | 0.75 | NOTUM (0.48) | NPY5RNOTUM | |
| SCHEMBL17436145 | 0.74 | NOTUM (0.59) | NOTUMPOLBKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL23451690 | 0.74 | KDM4E (0.47) | NOTUMPOLBKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL31330416 | 0.70 | NOTUM (0.43) | NPY5RNOTUM | |
| SCHEMBL31519343 | 0.69 | CYP2C9 (0.71) | NLRP3KDM4ESMN1; SMN2HSD17B10CYP2C9 | |
| SCHEMBL12940014 | 0.68 | SLC6A2 (0.43) | NPY5RNLRP3NOTUM | |
| SCHEMBL3349097 | 0.68 | MAPT (0.46) | NLRP3POLBKDM4ESMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739684-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008060-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |